Vernalis PLC (VER.L)
90.00GBp
23 Dec 2009
0.00p (+0.00%)
90.00p
90.00p
90.00p
90.00p
10,292
4,658
111.00p
39.40p
VER.L
About
Overall
| Beta: | 1.38 |
| Market Cap (Mil.): | £52.31 |
| Shares Outstanding (Mil.): | 58.12 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| VER.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 6.47 | 4.64 |
| EPS (TTM): | -153.43 | -- | -- |
| ROI: | -43.89 | 6.10 | 2.82 |
| ROE: | -94.33 | 9.08 | 3.58 |
UPDATE 1-Glaxo, Vernalis sign up to $200 mln cancer deal
* Vernalis gets $6 mln upfront, up to $200 mln in milestones
Vernalis CEO says M&A takes about half his time
LONDON (Reuters) - British biotech company Vernalis said on Tuesday about half its management time is taken up by efforts to secure an acquisition, suggesting a deal first promised last November may be getting closer.
UK Stocks -- Factors to watch on June 25
LONDON, June 25 (Reuters) - Britain's FTSE 100 index is seen opening 3-15 points lower on Thursday, according to financial bookmakers, retreating following a mixed performance on Wall Street after Federal Reserve comments failed to excite.
STOCKS NEWS EUROPE-Vernalis soars after Korea update
Shares in British biotechnology company Vernalis soar 13 percent after the company announces that its Korean partner SK Chemicals has gained approval to market its frovatriptan drug in South Korea.
STOCKS NEWS UK SMALL-Vernalis soars after Korea update
STOCKS NEWS Reuters Results diary
Consolidation may immunise biotech investors
LONDON (Reuters) - After seeing the value of investments tumble in the credit crisis, an emerging trend of industry consolidation in the UK biotech sector could be a welcome shot in the arm for investors.
Consolidation may immunise biotech investors
LONDON (Reuters) - After seeing the value of investments tumble in the credit crisis, an emerging trend of industry consolidation in the UK biotech sector could be a welcome shot in the arm for investors.
Biotech firm Vernalis' new CEO pledges change
LONDON (Reuters) - Vernalis on Friday appointed the former management team from Acambis to head the British biotechnology company, and the group's incoming Chief Executive promised significant changes.
UK biotech firm Vernalis' new CEO pledges change
* Incoming CEO says company "will not be what it is today"
STOCKS NEWS UK SMALL-Asterand up on bullish trading statement
STOCKS NEWS Reuters Results diary
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
